Nav: Home

Call time on costly drug to curb excess drinking, say dtb editors

September 07, 2016

The decision to green-light the drug nalmefene for curbing excess drinking among those who are alcohol dependent should be overturned, and the manufacturer compelled to provide solid evidence of its effectiveness, say the editors of the Drug and Therapeutics Bulletin (dtb) in an editorial in the latest issue.

Nalmefene, which interferes with the reward mechanisms in the brain, triggered by alcohol consumption, has been available as a daily tablet for use in the UK since 2013 for those who don't require an immediate detox.

It was approved for use in the NHS in England by the National Institute for Health and Care Excellence (NICE) in 2014, since when expenditure on the drug in primary care has quintupled to about £15,000 a month in England.

But when dtb reviewed the evidence on which that decision was based, the editors expressed doubts about its approval.

"We concluded that we could not recommend its use 'based on the limitations of the evidence, the relatively modest reductions in drinking compared with placebo, lack of evidence on health-related outcomes and concerns over the generalisability of the data'," they wrote at the time.

Since then three groups of researchers have highlighted several issues relating to the licensing and approval of nalmefene. These include that none of the studies specifically targeted the people for whom the drug was licensed, and that the licensing criteria were based on an ad hoc analysis of subsidiary data.

Furthermore, none of the trials compared nalmefene with any other drug, and the outcomes were not fully specified before the trials started.

And there was "no direct evidence" to show that it reduced harmful drinking, improved quality of life, or curbed other aspects of harmful behaviour associated with heavy drinking.

Additionally, it was unclear whether the trial data were relevant to UK clinical practice in primary care, the editors point out.

Last but not least, the level of counselling provided in the trials was less than that recommended by NICE, suggesting that the true costs of prescribing the drug are likely to be flawed, they suggest.

"Given such widespread concerns, we would urge agencies that appraise medicines on behalf of the NHS to revisit their decision," write the editors, adding: "The company should be required to produce more robust evidence to demonstrate that nalmefene results in clinically meaningful harm reduction."

And they query how the cost of the drug can be justified in such a cash-strapped era for the NHS.

"At a time when the NHS is removing some basic items from prescription, it seems incongruous that it continues to fund nalmefene despite having no real understanding of its actual impact on patient outcomes," they conclude.

In a podcast to accompany the September issue, dtb editor in chief Dr James Cave, insists: "We should not be using this drug."
-end-
Editorial: Nalmefene--time for last orders?
DOI 10.1136/dtb.2016.9.0421

About dtb:

The monthly Drug and Therapeutics Bulletin provides rigorous evaluations of, and practical advice on, individual treatment and the overall management of disease for doctors, pharmacists, and other healthcare professionals. The title is wholly independent of the pharmaceutical industry, government, and regulatory authorities. It carries no advertising or other forms of commercial sponsorship and is part of BMJ's Evidence Centre. http://dtb.bmj.com

BMJ

Related Primary Care Articles:

The need to reinvent primary care
Primary care is 'first-contact, continuous, comprehensive, and coordinated care provided to populations undifferentiated by gender, disease, or organ system.' High-quality primary care has been associated with improved population health, lower costs, and greater equity.
Affordable Care Act boosted primary care access for Medicaid patients
Since the introduction of the Affordable Care Act, which provided access to health insurance to millions of previously uninsured adults in the United States, the availability of appointments with primary care physicians has improved for patients with Medicaid and remains unchanged for patients with private coverage, according to new research.
Gauging ACA's effect on primary care access
A new research letter published online by JAMA Internal Medicine assessed the Affordable Care Act's effect on primary care access because millions of uninsured adults have gotten health insurance since major coverage provisions were implemented.
What primary care providers should know about diabetic neuropathy
Researchers at Michigan Medicine led a group of internationally recognized endocrinologists and neurologists from both sides of the Atlantic and teamed up with the American Diabetes Association to craft a new position statement on the prevention, treatment and management of diabetic neuropathy.
Most primary care doctors 'strongly endorse' key elements of the Affordable Care Act
Proponents of repealing the Affordable Care Act, including President Donald Trump's nominee for Secretary of Health and Human Services, Tom Price, have argued that the law places an undue burden on physicians.
Primary care physician involvement at end of life associated with less costly, less intensive care
A new study published in the January/February issue of Annals of Family Medicine finds that primary care physician involvement at the end of life is associated with less costly and less intensive end-of-life care.
Patients not attached to new primary care practices receive lower quality care
One in six patients in Ontario does not belong to an organized primary care practice, new research suggests.
Having primary care physician may not be enough to reduce ED visits by vulnerable groups
Having a regular family physician may not be enough to reduce emergency department visits among patients with disabilities, a small study published in Canadian Family Physician suggests.
Primary care physicians primed to help patients be more active
Exercise plays a crucial role in being healthy and preventing disease.
Primary care is point of entry for many kids with concussions
Many children with concussion initially sought care through primary care and not the emergency department, although younger children and those insured by Medicaid were more likely to go to the ED, according to an article published online by JAMA Pediatrics.

Related Primary Care Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...